|
|
Psychiatric study for cancer patients to measure psychoactive medication
Dec 31, 2004, 01:22, Reviewed by: Dr.
|
|
By Pankaj, US Correspondent,
Stage IV cancer patients who suffer from anxiety may want to investigate a research study approved by the Food and Drug Administration (FDA) taking place at LA BioMed. The specific aim of the study is to learn whether the psychoactive drug, psilocybin, might be effective in reducing anxiety, depression and physical pain, and therefore improving quality of life for Stage IV cancer patients. Psilocybin is a novel agent that produces a profound alteration in your state of consciousness.
The FDA recently approved a similar study at Harvard University to see whether the illegal drug ecstasy can ease the debilitating anxiety that cancer patients feel as they face their final days. 
- American Journal of Cardiology 2004 Nov 4; 94(9A): 22F-29F
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
To learn more about the study, see the project web site at www.canceranxietystudy.org. To contact the principal investigator of the study, Charles Grob, M.D., please call David Feuerherd at 310-215-0234 / 310-222-2820 or e-mail him at [email protected].
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
